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Table 1. Prevalence of antibodies against HHV-8 inHuman herpesvirus-8 Italian hemodialysis patients
No. of patients 97infection in hemodialysis Median age years (range) 69 (26.8–89.7)
Median dialysis time years (range) 5.9 (0.3–22.7)
Male/female ratio 53/44patients from northern Italy
HHV-8 positivea 9 (9.2%)
Hepatitis C virus (HCV) positive 13 (22.8%)To the Editor: Early epidemiologic studies showed
a The HHV-8 positive patients were 7 female and 2 male, with a median agethat the incidence of Kaposis’s sarcoma (KS) in renal
of 74.2 years (28.5 to 80.5 years), and with a median dialysis time of 8.0 years
transplant patients is 400 to 500 times more frequent (1.9 to 15.6 years). Two were also HCV positive.
than in a control population of the same ethnic origin
[1]. Recent molecular and serological studies have sug-
gested a pathogenetic involvement of human herpesvi- a relatively high prevalence of HHV-8 infection in “the
rus-8 (HHV-8) infection in all forms of KS, including healthy population.”
post-transplant KS [2]. Relevant to this, antibodies to
HHV-8 have been detected in the sera of most renal Mario Luppi, Lorenza Vandelli, Denise Whitby,
Anna Maria Savazzi, Patrizia Barozzi, Giuseppe Medici,transplant recipients before immunesuppressive treat-
Alberto Albertazzi, and Giuseppe Torelliment, suggesting that KS is mainly due to virus reactiva-
Department of Medical Sciences, Section of Hematology,
tion, although occurrence of HHV-8 transmission by do- and Nephrology Unit, Modena, Italy;
and Institute of Cancer Research, Chester Beatty Laboratories,nor’s allograft has been documented [3]. We tested the
London, England, United Kingdomhypothesis that either the uremic state or hemodialysis,
both of which are known to be associated with a high
NOTE ADDED IN PROOFsusceptibility to viral infections, may confer an increased
risk of developing KS by increasing the risk of exposure Recently, it has been reported that HHV-8 is transmitted
through renal allografts and is a risk factor transplantation-to HHV-8 infection. The prevalence of antibodies against
associated KS [Regamey N, Tamm N, Wernli M, Witschithe HHV-8 latent nuclear antigen (LNA-1) was investi-
A, Thiel G, Cathomas G, Erb P: Transmission of humangated with an immunofluorescence assay in 97 hemodial-
herpesvirus 8 infection from renal-transplant donors toysis patients and in 71 blood donors from the lower Po
recipients. New Engl J Med 339:1358–1363, 1998].valley of northern Italy, an area with one of the highest
incidence rates of classic KS in the world (Table 1). Sera
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